Fiche centre
University of Calgary
Calgary — Canada
Essais liés17clinical trials
VilleCalgarylocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06570473
Essais cliniques associés
17| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Nabilone | Alzheimer | Phase 3 | NCT04516057 | NAB-IT — Nabilone for Agitation Blinded Intervention Trial | RECRUITING |
| Tenecteplase | Accident vasculaire cérébral | Phase 3 | NCT06320431 | ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 | RECRUITING |
| Tofersen | Sclérose latérale amyotrophique | Phase 3 | NCT04856982 | ATLAS — Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | ACTIVE_NOT_RECRUITING |
| BB-031 | Accident vasculaire cérébral | Phase 2 | NCT06226805 | Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | RECRUITING |
| Empagliflozin | Insuffisance cardiaque | Phase 2 | NCT06570473 | CRAVE — Feasibility Trial for a Right Ventricular Failure Platform Trial | RECRUITING |
| BAROSTIM NEO System | Hypertension | Non applicable | NCT01471834 | Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension | ACTIVE_NOT_RECRUITING |
| Remote ischemic conditioning | SEP | Non applicable | NCT06171334 | Remote Ischemic Conditioning in PPMS | NOT_YET_RECRUITING |
| THC | SEP | Phase 2 | NCT06261489 | Cannabis (THC vs. CBD) in Multiple Sclerosis | RECRUITING |
| Nerandomilast | Myopathies | Phase 3 | NCT07789015 | VERANDA™-IIM — A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | NOT_YET_RECRUITING |
| Emapalumab | Lupus | Phase 3 | NCT05001737 | EMERALD — Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE | COMPLETED |
| CBD | Alzheimer | Phase 2 | NCT06014424 | CALM-IT — Cannabidiol Medication Intervention Trial | RECRUITING |
| 23-PPV | SEP | Phase 3 | NCT02545868 | A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis | COMPLETED |
| Acoramidis | Alzheimer | Phase 3 | NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | RECRUITING |
| PGN-EDODM1 | Myopathies | Phase 2 | NCT06667453 | FREEDOM2-DM1 — A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 | RECRUITING |
| SRP-1001 for Injection | Myopathies | Phase 1/2 | NCT06131983 | Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 | ENROLLING_BY_INVITATION |
| SRP-1003 IV Infusion | Myopathies | Phase 1/2 | NCT06138743 | Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | ENROLLING_BY_INVITATION |
| Perindopril | Alzheimer | Phase 2 | NCT02085265 | Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients | TERMINATED |